World Alzheimer’s Day 2022

An estimated 50 million people around the world currently live with Alzheimer's disease or other dementias, dementia being a collective term for progressive syndromes that affect various expressions of cognitive function, such as memory and emotional expression. Alzheimer’s disease accounts for the majority of cases (50 to 70%, varying by country, based on Alzheimer’s Disease International and World Health Organization figures). For those directly affected and their loved ones, dementia can be a frightening experience, particularly as it is so poorly understood. However there remains little or no understanding of dementia in many, and the stigmatization and misinformation that surrounds dementia remains a global issue.

For 2022 World Alzheimer’s Day the theme Know Dementia, Know Alzheimer’s, organized annually by Alzheimer’s Disease International, focuses on diagnosis, the warning signs of dementia, with a special focus on post-diagnosis support. The aim of this international campaign is to highlight the importance of support for people living with dementia and families following a diagnosis.

Elsevier,

Autophagy in Health and Disease, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by reviewing the extant literature on autophagy in AD and covers recent progress on the molecular mechanisms of NAD+-dependent mitophagy/autophagy regulation and mechanisms underlying the anti-AD potential of NAD+. Further studies to define the NAD+-mitophagy/autophagy axis may shed light on novel therapeutics to treat AD and potentially provide insights into other neurodegenerative diseases.
Elsevier,

Assessments, Treatments and Modeling in Aging and Neurological Disease: The Neuroscience of Aging, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by reviewing the use of nonhuman primates as a viable model of aging and neurodegeneration research.
Elsevier,

International Review of Neurobiology, Volume 159, January 2021

This book chapter advances SDG #3 and #10 by reviewing deep brain stimulation as a treatment for AD patients, reviewing the recent studies and issues associated with the treatment.
Elsevier,

Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by outlining how both the asymptomatic and symptomatic predementia phases of AD, amyloid positivity using amyloid PET imaging could predict progression to AD dementia. Amyloid PET imaging can identify the status of Aβ deposition in the underlying AD pathophysiology, increase diagnostic certainty, and alter management. This approach could improve the diagnose and management for patients with memory loss or cognitive dysfunction.
Elsevier,

Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by focusing on providing a brief overview of genes associated with sporadic (late-onset) Alzheimer's disease (AD).
Elsevier,

Handbook of Mental Health and Aging, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by reviewing background on neurocognitive disorders, approaches to diagnosis, and management of several of the more problematic psychiatric complications of dementia. Disorders reviewed include AD, vascular dementia, Lewy body disease, and frontotemporal dementia. Psychiatric symptoms reviewed include apathy, agitation, psychosis, depression, and anxiety.
Elsevier,

Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1, Volume , 1 January 2020

This book chapter advances SDG #3 and #10 by providing an overview of natural AChE inhibitors extracted from plants and their therapeutic potential to treat AD.
Elsevier,

Neuroprotection in Alzheimer's Disease, Volume , 20 January 2017

This book chapter advances SDG #3 and #10 by reviewing neural regeneration–based therapeutic approaches as it represents a highly promising therapeutic strategy for AD, including research that CNTF small-molecule peptide mimetic has demonstrated that neural regeneration–based strategy can also be disease modifying for AD.
Elsevier,

Handbook of Clinical Neurology, Volume 179, January 2021

This book chapter advances SDG #3 and #10 by reviewing the observed epidemiological links between normal and abnormal diurnal and seasonal rhythmicity, cognitive impairment, and ADRD. Then reviewing normal diurnal and seasonal rhythms of brain epigenetic modification and gene expression in model organisms. Finally, reviewing evidence for diurnal and seasonal rhythms of epigenetic modification and gene expression the human brain in aging, Alzheimer's disease, and other brain disorders.
Elsevier,

Handbook of Clinical Neurology, Volume 184, January 2022

This book chapter advances SDG #3 and #10 by reviewing studies that showed treatments with multiple sessions of rTMS can influence cognition in people with neurodegenerative diseases. The chapter also considers novel therapeutic approaches based on the clinical use of rTMS.

Pages